This post-conference overview of the ASGCT Annual Meeting 2023 highlights key developments and research trends in gene and cell therapy. Oncology represented the largest share of presented abstracts at 25%, followed by Neurology at 20%, Metabolic disorders at 15.6%, and Musculo-skeletal disorders at 12%, reflecting continued innovation across multiple therapeutic areas. In Oncology, 25 clinical data presentations were featured, with 56% focused on solid tumors and the remainder on hematological cancers, signaling a growing shift in research attention toward solid tumor therapies. The conference showcased a mix of clinical and preclinical studies from various sponsor groups, highlighting advances in gene editing, cell therapy, and rare disease treatments. Overall, the event underscored the

Join for free to read